Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1287)	3/14/2005 5:08:35 PM
From: Mike McFarland	Respond to of 1298

There are two oncolytic adenovirus abstracts at aacr.org, these are mice experiments with CG5757, and CG0070. There are three more that have to do with improving delivery of these. Several abstracts have to do with growth factors. A couple of the abstracts happen to use AAV delivery (for instance "VEGF blockade using AAV-sVEGFR1/R2"). That last one, in mice, seems to have a synergistic effect when used with Avastin, which caught my eye because of DNA today. There are also seven posters. fwiw, I have become somewhat convinced that gvax is not the right reason to buy cege, but rather a good bet might be to get into the shares if gvax doesn't work out. Obviously, the shares lit up in the last hour today, so what do I know. Sentiment can sure turn on a dime. edit, I just checked out the Yahoo board and somebody linked to my previous post. That cannot be good. They probably don't know I am often a contrary indicator, ha!